Drug intelligence / Profile preview

Zhilong Tongluo

Development stage: Unknown
Lead developer: 北京同御康泰科技
Administration: Oral

Overview

Zhilong Tongluo is a Traditional Chinese Medicine (TCM) formulation, specifically a tablet, developed by Beijing Tongyu Kangtai Technology for the treatment of ischemic stroke during the convalescent stage. The medication is designed for patients diagnosed with Qi deficiency and blood stasis syndrome according to TCM principles. It typically contains animal-derived ingredients such as *Hirudo* (leech) and *Pheretima* (earthworm), which are traditionally used to promote blood circulation and clear collateral vessels. The drug is currently in Phase III clinical development in China to evaluate its efficacy in improving neurological deficits and functional recovery following cerebral infarction.

Brand names: Zhilong Tongluo
Other names: Zhilong Tongluo Tablet滞龙通络片

Targets

Fibrin (Factor Ia)F2 (Thrombin)

Beyond the preview

Go deeper on Zhilong Tongluo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhilong Tongluo.

Explore the full profile